SheMed Secures €43M To Expand Personalised Women’s Healthcare In The UK

The funding will expand UK operations, grow medical and tech teams, strengthen clinical infrastructure, and enhance data-driven capabilities to advance innovations in preemptive healthcare.

“For more than a decade, I searched for answers to an undiagnosed health issue,” said Olivia Ferro, Co-founder and CEO of SheMed. “As a GLP-1 patient myself, I know how transformative the right diagnosis and treatment can be. We built SheMed to give women the personalised support I struggled to find: care that listens, understands and empowers.”

SheMed’s latest funding comes amid a broader 2025 surge in UK and European HealthTech investment, with a focus on preventative care and women’s health. Other UK startups attracting significant capital include Numan (€51.6M) for female-focused digital health, Hormona (€7.8M) for AI-driven hormone tracking, and ventures like Perci Health and CoMind advancing personalised, data-led healthcare solutions.

Read Also - Rightcharge Secures £1.6M To Streamline EV Charging Payments For European Fleets

“The demand for SheMed’s services has been extraordinary,” added Chloe Ferro, Co-founder and President of SheMed. “Women are seeking care that recognises their individuality, their biology and their experiences. It’s why women continue to turn to SheMed for a tailored, more supportive path to healthcare.”

EU-Startups reports that UK startups have raised approximately €14.7 billion in 2025 so far, highlighting strong investor confidence in the nation’s innovation ecosystem. In this context, SheMed’s funding underscores both the country’s HealthTech momentum and increasing investor focus on women’s health and metabolic-care platforms as key growth areas in Europe.

Founded in April 2024 by sisters Olivia and Chloe Ferro, SheMed has quickly become a leader in women’s healthcare, addressing gaps in access to personalised, reliable, and sustainable solutions.

The platform combines medical oversight, wellness tracking, and 24/7 support, delivering tailored care while redefining digital healthcare for women.

The new funding will expand research and patient-experience initiatives, improving access to high-quality, personalised care across the UK.

SheMed is best known for its GLP-1 and weight-management programme, which integrates medical expertise, data insights, and ongoing support to help women achieve lasting health outcomes.

In under a year, SheMed has served 60,000+ members, establishing itself as the fastest-growing GLP-1 programme in the UK. Later this month, the company will release results from the first-ever female-focused GLP-1 clinical study, providing critical insights into women’s hormonal and metabolic responses to guide future treatments.

About SheMed

SheMed is a female-founded HealthTech company transforming women’s healthcare. The platform delivers personalized, test-to-treat solutions, empowering women with knowledge, tools and support to take control of their health, achieve lasting well-being, and thrive within a compassionate, innovative and community-driven environment.